scar

(redirected from Hypertrophic scar)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia.
References in periodicals archive ?
Hypertrophic scars and keloids--a review of their pathophysiology, risk factors, and therapeutic management.
Keloids and hypertrophic scars are characterized by uncontrolled cellular proliferation that forms unsightly, raised, reddish lesions on the skin.
In December 2014, the Company announced results from preliminary data in its first Phase 2a clinical trial for hypertrophic scars, Study 1301.
Such studies might lead to improvements in the application vehicle and in the prevention of hypertrophic scars over the long term.
Talsyn[TM], a unique, all natural Lipid-Peptide combination of ingredients used for the management of keloids, hypertrophic scars, erythema and surgical incisions; and Infinitink[R], a permanent, yet more easily removable, tattoo ink.
These products and procedures are used to treat all types of scars, such as keloid scars, contracture scars, hypertrophic scars, and atrophic scars.
Talsyn[TM], a unique, all natural Lipid-Peptide combination of ingredients used for the management of keloids, hypertrophic scars, erythema, and surgical incisions; and Infinitink[R], a permanent, yet more easily removable, tattoo ink.
RXI-109 for hypertrophic scars and keloids post scar revision surgery.
Three Phase 2a clinical trials are currently underway to evaluate the effectiveness and safety of RXICae109 on the outcome of scar revision surgeries performed on hypertrophic scars resulting from lower abdominal surgeries (RXICae109Cae1301), to evaluate the effectiveness and safety of RXICae109 in healthy subjects who undergo an elective surgical excision of two similarly sized and placed keloids (RXICae109Cae1401) and the outcome of scar revision surgeries performed on hypertrophic scars (RXI-109-1402).
using Nuvilex intellectual property; Talsyn[TM], a Lipid-Peptide compound used for the management of keloids, hypertrophic scars, erythema and surgical incisions; and Infinitink[R], a permanent yet more easily removable tattoo ink.
7, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that a review of the first two enrolled patients' clinical photographs in the first Phase 2a clinical trial (RXI-109-1301), indicate that treatment with the Company's lead clinical candidate, RXI-109, may be effective in suppressing recurrence of hypertrophic scars at the 3-month time point.
He added that, "The interim findings in the first Phase 2a trial with RXI-109 are of significant help in accelerating the evaluation of the best treatment regimen for patients with hypertrophic scars, allowing for additional patients to be included in cohorts with a more effective dosing regimen and saving time and costs by eliminating less optimal treatment schedules.